References
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405–12 (PMID: 10938048).
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89 (PMID: 18784090).
Writing Group for the DCCT/EDIC Research Group, Orchard TJ, Nathan DM, Zinman B, Cleary P, Brillon D, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015;313:45–53 (PMID: 25562265).
Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–72 (PMID: 19465231).
Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013;CD008143 (PMID: 24214280).
Kähler P, Grevstad B, Almdal T, Gluud C, Wetterslev J, Lund SS, et al. Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: Systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ Open. 2014;4:E004806 (PMID: 25138801).
Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014:CD009122 (PMID: 24526393).
DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397–405 (PMID: 11176766).
Nakagami T, DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47:385–94 (PMID: 14985967).
Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care. 1999;22:920–4 (PMID: 10372242).
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486–94 (PMID: 12876091).
Oka R, Aizawa T, Miyamoto S, Yoneda T, Yamagishi M. One-hour plasma glucose as a predictor of the development of Type 2 diabetes in Japanese adults. Diabet Med. 2016;33:1399–405 (PMID: 26482027).
Alyass A, Almgren P, Akerlund M, Dushoff J, Isomaa B, Nilsson P, et al. Modelling of OGTT curve identifies 1 h plasma glucose level as a strong predictor of incident type 2 diabetes: Results from two prospective cohorts. Diabetologia. 2015;58:87–97 (PMID: 25292440).
Japan Diabetes Society. Treatment guide for diabetes 2018–2019. Tokyo: Bunkodo; 2018 (in Japanese).
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34 (PMID: 9673301).
Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22 (PMID: 20609967).
Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12:56–62 (PMID: 3379219).
Alpert JS. Myocardial infarction with angiographically normal coronary arteries. Arch Intern Med. 1994;154:265–9 (PMID: 8297192).
Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al., Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59 (PMID: 18539917).
Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al., Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380:1649–61 (PMID: 23013600).
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635–701 (PMID: 22555213).
D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation. 2008;117:743–53 (PMID: 18212285).
Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(Suppl):S49–73 (PMID: 24222018).
Kengne AP, Batty GD, Hamer M, Stamatakis E, Czernichow S. Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: Pooled analyses of 25,979 participants from four U.K. prospective cohort studies. Diabetes Care. 2012;35:396–3 (PMID: 22210562).
Ridker PM. A test in context: High-sensitivity C-reactive protein. J Am Coll Cardiol. 2016;67:712–23 (PMID: 26868696).
Djaberi R, Beishuizen ED, Pereira AM, Rabelink TJ, Smit JW, Tamsma JT, et al. Non-invasive cardiac imaging techniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus. Diabetologia. 2008;51:1581–93 (PMID: 18607561).
Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314–9 (PMID: 7867167).
Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003;41:1769–75 (PMID: 12767663).
Lee CD, Folsom AR, Pankow JS, Brancati FL, Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation. 2004;109:855–60 (PMID: 14757692).
Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997;96:1432–7 (PMID: 9315528).
Cuspidi C, Lonati L, Macca G, Sampieri L, Fusi V, Severgnini B, et al. Cardiovascular risk stratification in hypertensive patients: Impact of echocardiography and carotid ultrasonography. J Hypertens. 2001;19:375–80 (PMID: 11288806).
Greenland P, Abrams J, Aurigemma GP, Bond MG, Clark LT, Criqui MH, et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: Noninvasive tests of atherosclerotic burden: Writing Group III. Circulation. 2000;101:E16–22 (PMID: 10618318).
Perez HA, Garcia NH, Spence JD, Armando LJ. Adding carotid total plaque area to the Framingham risk score improves cardiovascular risk classification. Arch Med Sci. 2016;12:513–20 (PMID: 27279842).
Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355–74 (PMID: 7648691).
Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–32 (PMID: 2407762).
Hoff JA, Quinn L, Sevrukov A, Lipton RB, Daviglus M, Garside DB, et al. The prevalence of coronary artery calcium among diabetic individuals without known coronary artery disease. J Am Coll Cardiol. 2003;41:1008–12 (PMID: 12651050).
Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O’Leary D, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308:788–95 (PMID: 22910756).
Elkeles RS, Godsland IF, Feher MD, Rubens MB, Roughton M, Nugara F, et al., PREDICT Study Group. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: The PREDICT study. Eur Heart J. 2008;29:2244–51 (PMID: 18573867).
Anand DV, Lim E, Hopkins D, Corder R, Shaw LJ, Sharp P, et al. Risk stratification in uncomplicated type 2 diabetes: Prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J. 2006;27:713–21 (PMID: 16497686).
Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol. 2004;43:1663–9 (PMID: 15120828).
Standards of Medical Care in Diabetes–2016: Summary of revisions. Diabetes Care. 2016;39(Suppl):S4–S5 (PMID: 26696680).
Raggi P, Callister TQ, Shaw LJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol. 2004;24:1272–7 (PMID: 15059806).
Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol. 2005;46:158–65 (PMID: 15992651).
Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I: aging arteries: a “set up” for vascular disease. Circulation. 2003;107:139–46 (PMID: 12515756).
Simons PC, Algra A, Bots ML, Grobbee DE, van der Graaf Y. Common carotid intima-media thickness and arterial stiffness: Indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation. 1999;100:951–57 (PMID: 10468526).
Störk S, van den Beld AW, von Schacky C, Angermann CE, Lamberts SW, Grobbee DE, et al. Carotid artery plaque burden, stiffness, and mortality risk in elderly men: A prospective, population-based cohort study. Circulation. 2004;110:344–8 (PMID: 15238459).
Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006;113:664–70 (PMID: 16461839).
Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:E686–725 (PMID: 27840332).
Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004;109:733–9 (PMID: 14970108).
Criqui MH, McClelland RL, McDermott MM, Allison MA, Blumenthal RS, Aboyans V, et al. The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010;56:1506–12 (PMID: 20951328).
Doobay AV, Anand SS. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol. 2005;25:1463–9 (PMID: 15879302).
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;12(Suppl):S1-45 (PMID: 24222016).
Paillole C, Ruiz J, Juliard JM, Leblanc H, Gourgon R, Passa P. Detection of coronary artery disease in diabetic patients. Diabetologia. 1995;38:726–31 (PMID: 7672497).
Elhendy A, van Domburg RT, Poldermans D, Bax JJ, Nierop PR, Geleijnse ML, et al. Safety and feasibility of dobutamine-atropine stress echocardiography for the diagnosis of coronary artery disease in diabetic patients unable to perform an exercise stress test. Diabetes Care. 1998;21:1797–802 (PMID: 9802723).
Japan Diabetes Society. Japanese clinical practice guideline for diabetes 2019. Tokyo: Nankodo; 2019 (in Japanese).
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81 (PMID: 27222591).
Raff GL, Gallagher MJ, O’Neill WW, Goldstein JA. Diagnostic accuracy of noninvasive coronary angiography using 64-slice spiral computed tomography. J Am Coll Cardiol. 2005;46:552–7 (PMID: 16053973).
Mollet NR, Cademartiri F, van Mieghem CA, Runza G, McFadden EP, Baks T, et al. High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation. 2005;112:2318–23 (PMID: 16203914).
Hoffmann U, Moselewski F, Nieman K, Jang IK, Ferencik M, Rahman AM, et al. Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. J Am Coll Cardiol. 2006;47:1655–62 (PMID: 16631006).
Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol. 1974;34:29–34 (PMID: 4835750).
Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24:1614–9 (PMID: 11522708).
Thrainsdottir IS, Aspelund T, Hardarson T, Malmberg K, Sigurdsson G, Thorgeirsson G, et al. Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavík Study. Eur J Cardiovasc Prev Rehabil. 2005;12:465–71 (PMID: 16210933).
Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005;28:612–6 (PMID: 15735197).
Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3:105–13 (PMID: 25466521).
Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27:699–703 (PMID: 14988288).
Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668–73 (PMID: 11390335).
Barzilay JI, Kronmal RA, Gottdiener JS, Smith NL, Burke GL, Tracy R, et al. The association of fasting glucose levels with congestive heart failure in diabetic adults > or =65 years: the Cardiovascular Health Study. J Am Coll Cardiol. 2004;43:2236–41 (PMID: 15193686).
Metra M, Zacà V, Parati G, Agostoni P, Bonadies M, Ciccone M, et al., Heart Failure Study Group of the Italian Society of Cardiology. Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. J Cardiovasc Med (Hagerstown). 2011;12:76–84 (PMID: 20962666).
MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al., CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377–85 (PMID: 18413309).
Falcão-Pires I, Hamdani N, Borbély A, Gavina C, Schalkwijk CG, van der Velden J, et al. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation. 2011;124:1151–9 (PMID: 21844073).
Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J. 2014;35:657–64 (PMID: 23756336).
Shimizu I, Minamino T, Toko H, Okada S, Ikeda H, Yasuda N, et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest. 2010;120:1506–14 (PMID: 20407209).
Levelt E, Rodgers CT, Clarke WT, Mahmod M, Ariga R, Francis JM, et al. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur Heart J. 2016;37:3461–9 (PMID: 26392437).
Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al., Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure: Digest version. Circ J. 2019;83:2084–184 (PMID: 31511439).
Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005;105:315–8 (PMID: 16274775).
Hofman A, van Duijn CM, Franco OH, Ikram MA, Janssen HL, Klaver CC, et al. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol. 2011;26:657–86 (PMID: 21877163).
Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271:840–4 (PMID: 8114238).
Iguchi Y, Kimura K, Aoki J, Kobayashi K, Terasawa Y, Sakai K, et al. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: Analysis of 41,436 non-employee residents in Kurashiki-city. Circ J. 2008;72:909–13 (PMID: 18503215).
Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011;108:56–62 (PMID: 21529739).
Murphy NF, Simpson CR, Jhund PS, Stewart S, Kirkpatrick M, Chalmers J, et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart. 2007;93:606–12 (PMID: 17277353).
Tayebjee MH, Lim HS, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year’s cardiovascular risk reduction therapy. Diabetes Care. 2004;27:2049–51 (PMID: 15277439).
Lim HS, MacFadyen RJ, Lip GY. Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. Arch Intern Med. 2004;164:1737–48 (PMID: 15364666).
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70 (PMID: 11401607).
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263–72 (PMID: 19762550).
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837–47 (PMID: 24345399).
Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: Results from a population-based study. Stroke. 2005;36:1115–9 (PMID: 15879330).
Umpierre D, Ribeiro PA, Kramer CK, Leitão CB, Zucatti AT, Azevedo MJ, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011;305:1790–9 (PMID: 21540423).
Boulé NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286:1218–27 (PMID: 11559268).
Pai LW, Li TC, Hwu YJ, Chang SC, Chen LL, Chang PY. The effectiveness of regular leisure-time physical activities on long-term glycemic control in people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2016;113:77–85 (PMID: 26822261).
Boniol M, Dragomir M, Autier P, Boyle P. Physical activity and change in fasting glucose and HbA1c: a quantitative meta-analysis of randomized trials. Acta Diabetol. 2017;54:983–91 (PMID: 28840356).
MacLeod SF, Terada T, Chahal BS, Boulé NG. Exercise lowers postprandial glucose but not fasting glucose in type 2 diabetes: a meta-analysis of studies using continuous glucose monitoring. Diabetes Metab Res Rev. 2013;29:593–603 (PMID: 24038928).
Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care. 2006;29:2518–27 (PMID: 17065697).
Qiu S, Cai X, Schumann U, Velders M, Sun Z, Steinacker JM. Impact of walking on glycemic control and other cardiovascular risk factors in type 2 diabetes: a meta-analysis. PLoS ONE. 2014;9:E109767 (PMID: 25329391).
Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;(3):CD002968 (PMID: 16855995).
Sabag A, Way KL, Keating SE, Sultana RN, O’Connor HT, Baker MK, et al. Exercise and ectopic fat in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2017;43:195–210 (PMID: 28162956).
Way KL, Hackett DA, Baker MK, Johnson NA. The effect of regular exercise on insulin sensitivity in type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab J. 2016;40:253–71 (PMID: 27535644).
Schwingshackl L, Missbach B, Dias S, König J, Hoffmann G. Impact of different training modalities on glycaemic control and blood lipids in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetologia. 2014;57:1789–97 (PMID: 24996616).
Kelley GA, Kelley KS. Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: a Meta-analysis of randomized-controlled trials. Public Health. 2007;121:643–55 (PMID: 17544042).
Hayashino Y, Jackson JL, Fukumori N, Nakamura F, Fukuhara S. Effects of supervised exercise on lipid profiles and blood pressure control in people with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2012;98:349–60 (PMID: 23116535).
Chudyk A, Petrella RJ. Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis. Diabetes Care. 2011;34:1228–37 (PMID: 21525503).
Hayashino Y, Jackson JL, Hirata T, Fukumori N, Nakamura F, Fukuhara S, et al. Effects of exercise on C-reactive protein, inflammatory cytokine and adipokine in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Metabolism. 2014;63:431–40 (PMID: 24355625).
Figueira FR, Umpierre D, Cureau FV, Zucatti AT, Dalzochio MB, Leitão CB, et al. Association between physical activity advice only or structured exercise training with blood pressure levels in patients with type 2 diabetes: a systematic review and meta-analysis. Sports Med. 2014;44:1557–72 (PMID: 25047852).
Melo LC, Dativo-Medeiros J, Menezes-Silva CE, Barbosa FT, de Sousa-Rodrigues CF, Rabelo LA. Physical exercise on inflammatory markers in type 2 diabetes patients: a systematic review of randomized controlled trials. Oxid Med Cell Longev. 2017;2017:8523728 (PMID: 28400914).
Boulé NG, Kenny GP, Haddad E, Wells GA, Sigal RJ. Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in Type 2 diabetes mellitus. Diabetologia. 2003;46:1071–81 (PMID: 12856082).
Jelleyman C, Yates T, O’Donovan G, Gray LJ, King JA, Khunti K, et al. The effects of high-intensity interval training on glucose regulation and insulin resistance: a meta-analysis. Obes Rev. 2015;16:942–61 (PMID: 26481101).
American Diabetes Association. 4: Lifestyle management: standards of medical care in diabetes–2018. Diabetes Care. 2018;41(Suppl):S38–50 (PMID: 29222375).
Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39:2065–79 (PMID: 27926890).
Oliveira C, Simões M, Carvalho J, Ribeiro J. Combined exercise for people with type 2 diabetes mellitus: a systematic review. Diabetes Res Clin Pract. 2012;98:187–98 (PMID: 22981711).
Yang Z, Scott CA, Mao C, Tang J, Farmer AJ. Resistance exercise versus aerobic exercise for type 2 diabetes: a systematic review and meta-analysis. Sports Med. 2014;44:487–99 (PMID: 24297743).
Nery C, Moraes SRA, Novaes KA, Bezerra MA, Silveira PVC, Lemos A. Effectiveness of resistance exercise compared to aerobic exercise without insulin therapy in patients with type 2 diabetes mellitus: a meta-analysis. Braz J Phys Ther. 2017;21:400–15 (PMID: 28728958).
Hovanec N, Sawant A, Overend TJ, Petrella RJ, Vandervoort AA. Resistance training and older adults with type 2 diabetes mellitus: strength of the evidence. J Aging Res. 2012;2012:284635 (PMID: 22988507).
Katzmarzyk PT, Church TS, Craig CL, Bouchard C. Sitting time and mortality from all causes, cardiovascular disease, and cancer. Med Sci Sports Exerc. 2009;41:998–1005 (PMID: 19346988).
Dempsey PC, Larsen RN, Sethi P, Sacre JW, Straznicky NE, Cohen ND, et al. Benefits for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking or simple resistance activities. Diabetes Care. 2016;39:964–72 (PMID: 27208318).
Kodama S, Tanaka S, Heianza Y, Fujihara K, Horikawa C, Shimano H, et al. Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: a meta-analysis. Diabetes Care. 2013;36:471–9 (PMID: 23349151).
Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: Joint position statement. Diabetes Care. 2010;33:E147–67 (PMID: 21115758).
Liubaoerjijin Y, Terada T, Fletcher K, Boulé NG. Effect of aerobic exercise intensity on glycemic control in type 2 diabetes: a meta-analysis of head-to-head randomized trials. Acta Diabetol. 2016;53:769–81 (PMID: 27255501).
Dasgupta K, Rosenberg E, Joseph L, Cooke AB, Trudeau L, Bacon SL, et al., SMARTER Trial Group. Physician Step prescription and Monitoring to improve ARTERial health (SMARTER): a randomized controlled trial in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2017;19:695–704 (PMID: 28074635).
Baskerville R, Ricci-Cabello I, Roberts N, Farmer A. Impact of accelerometer and pedometer use on physical activity and glycaemic control in people with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2017;34:612–20 (PMID: 28173623).
Ministry of Health, Labour and Welfare. Japanese official physical activity references 2013 for health promotion [in Japanese]. 2013. https://www.mhlw.go.jp/stf/houdou/2r9852000002xple-att/2r9852000002xpqt.pdf. Accessed 1 Nov 2019.
Park SW, Goodpaster BH, Lee JS, Kuller LH, Boudreau R, de Rekeneire N, et al. Health, aging, and body composition study: excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care. 2009;32:1993–7 (PMID: 19549734).
Ogawa H, Adachi H, Hayashi T, Inoue T, Ishihara M, Ishii H, et al, JCS Joint Working Group. Guidelines for secondary prevention of myocardial infarction (JCS 2011). Circ J 2013;77:231–248 (PMID: 23165785).
Nohara R, Adachi H, Goto Y, Hasegawa E, Ishihara S, Itoh H, et al, JCS Joint Working Group. Guidelines for rehabilitation in patients with cardiovascular disease (JCS 2012). Circ J 2014;78:2022–2093 (PMID: 25047729).
May GS, Eberlein KA, Furberg CD, Passamani ER, DeMets DL. Secondary prevention after myocardial infarction: a review of long-term trials. Prog Cardiovasc Dis. 1982;24:331–52 (PMID: 6119737).
Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2011;(7):CD001800 (PMID: 21735386).
van Halewijn G, Deckers J, Tay HY, van Domburg R, Kotseva K, Wood D. Lessons from contemporary trials of cardiovascular prevention and rehabilitation: a systematic review and meta-analysis. Int J Cardiol. 2017;232:294–303 (PMID: 28094128).
Dibben GO, Dalal HM, Taylor RS, Doherty P, Tang LH, Hillsdon M. Cardiac rehabilitation and physical activity: systematic review and meta-analysis. Heart. 2018;104:1394–402 (PMID: 29654095).
Dylewicz P, Bienkowska S, Szczesniak L, Rychlewski T, Przywarska I, Wilk M, et al. Beneficial effect of short-term endurance training on glucose metabolism during rehabilitation after coronary bypass surgery. Chest. 2000;117:47–51 (PMID: 10631198).
Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmö feasibility study. Diabetologia. 1991;34:891–8 (PMID: 1778354).
Schneider SH, Khachadurian AK, Amorosa LF, Clemow L, Ruderman NB. Ten-year experience with an exercise-based outpatient life-style modification program in the treatment of diabetes mellitus. Diabetes Care. 1992;15:1800–10 (PMID: 1468318).
Jiménez-Navarro MF, Lopez-Jimenez F, Pérez-Belmonte LM, Lennon RJ, Diaz-Melean C, Rodriguez-Escudero JP, et al. Benefits of cardiac rehabilitation on cardiovascular outcomes in patients with diabetes mellitus after percutaneous coronary intervention. J Am Heart Assoc. 2017;6:E006404 (PMID: 29021270).
Thomas RJ, King M, Lui K, Oldridge N, Piña IL, Spertus J, AACVPR. AACVPR, ACC, AHA, , et al. performance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention services endorsed by the American College of Chest Physicians, American College of Sports Medicine, American Physical Therapy Association, Canadian Association of Cardiac Rehabilitation, European Association for Cardiovascular Prevention and Rehabilitation, Inter-American Heart Foundation, National Association of Clinical Nurse Specialists, Preventive Cardiovascular Nurses Association, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2007;2007(50):1400–33 (PMID: 17903645).
Fletcher GF, Balady GJ, Amsterdam EA, Chaitman B, Eckel R, Fleg J, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:1694–740 (PMID: 11581152).
Zhu P, Pan XF, Sheng L, Chen H, Pan A. Cigarette smoking, diabetes, and diabetes complications: call for urgent action. Curr Diab Rep. 2017;17:78 (PMID: 28766247).
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Risk factors for cardiovascular disease in type 1 diabetes. Diabetes. 2016;65:1370–79 (PMID: 26895792).
Pan A, Wang Y, Talaei M, Hu FB. Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. Circulation. 2015;132:1795–804 (PMID: 26311724).
Mons U, Müezzinler A, Gellert C, Schöttker B, Abnet CC, Bobak M, et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: Meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ. 2015;350:H1551 (PMID: 25896935).
Clair C, Rigotti NA, Porneala B, Fox CS, D’Agostino RB, Pencina MJ, et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA. 2013;309:1014–21 (PMID: 23483176).
Akter S, Goto A, Mizoue T. Smoking and the risk of type 2 diabetes in Japan: a systematic review and meta-analysis. J Epidemiol. 2017;27:553–61 (PMID: 28716381).
Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29:2102–7 (PMID: 16936160).
Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al., Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54 (PMID: 23796131).
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93 (PMID: 12556541).
Sone H, Tanaka S, Iimuro S, Tanaka S, Oida K, Yamasaki Y, et al., Japan Diabetes Complications Study Group. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: A nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia. 2010;53:419–28 (PMID: 20054522).
Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, et al., J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:951–64 (PMID: 29079252).
Salehi-Abargouei A, Maghsoudi Z, Shirani F, Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases–incidence: a systematic review and meta-analysis on observational prospective studies. Nutrition. 2013;29:611–8 (PMID: 23466047).
Sofi F, Macchi C, Abbate R, Gensini GF, Casini A. Mediterranean diet and health status: An updated meta-analysis and a proposal for a literature-based adherence score. Public Health Nutr. 2014;17:2769–82 (PMID: 24476641).
Filippatos TD, Panagiotakos DB, Georgousopoulou EN, Pitaraki E, Kouli GM, Chrysohoou C, et al., ATTICA Study Group. Mediterranean diet and 10-year (2002–2012) incidence of diabetes and cardiovascular disease in participants with prediabetes: the ATTICA study. Rev Diabet Stud. 2016;13:226–35 (PMID: 28278309).
Campbell AP. DASH Eating Plan: An eating pattern for diabetes management. Diabetes Spectr. 2017;30:76–81 (PMID: 28588372).
Seidelmann SB, Claggett B, Cheng S, Henglin M, Shah A, Steffen LM, et al. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Health. 2018;3:E419–28 (PMID: 30122560).
Ministry of Health, Labour and Welfare. The dietary reference intakes for Japanese study group report. 2020 edn [in Japanese]. 2020. https://www.mhlw.go.jp/content/10904750/000586553.pdf Accessed 31 Jan 2020.
Department of Health and Human Services. Dietary guidelines for Americans 2015–2020. New York: Skyhorse Publishing Inc.; 2017.
Development Committee for Guidelines for the Management of Sarcopenia. Guidelines for the management of sarcopenia 2017. Tokyo: Life Science Publishing Co., Ltd.; 2017 (in Japanese).
Atkins JL, Whincup PH, Morris RW, Lennon LT, Papacosta O, Wannamethee SG. Sarcopenic obesity and risk of cardiovascular disease and mortality: a population-based cohort study of older men. J Am Geriatr Soc. 2014;62:253–60 (PMID: 24428349).
Byeon CH, Kang KY, Kang SH, Bae EJ. Sarcopenia is associated with Framingham risk score in the Korean population: Korean National Health and Nutrition Examination Survey (KNHANES) 2010–2011. J Geriatr Cardiol. 2015;12:366–72 (PMID: 26346573).
Horikawa C, Yoshimura Y, Kamada C, Tanaka S, Tanaka S, Hanyu O, et al, Japan Diabetes Complications Study Group. Dietary sodium intake and incidence of diabetes complications in Japanese patients with type 2 diabetes: analysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab. 2014;99:3635–43 (PMID: 25050990)
Ekinci EI, Clarke S, Thomas MC, Moran JL, Cheong K, MacIsaac RJ, et al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care. 2011;34:703–9 (PMID: 21289228).
Kengne AP, Patel A, Barzi F, Jamrozik K, Lam TH, et al., Asia Pacific Cohort Studies Collaboration. Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia–Pacific region. J Hypertens. 2007;25:1205–13 (PMID: 17563533).
Liu Y, Wang M, Morris AD, Doney AS, Leese GP, Pearson ER, et al. Glycemic exposure and blood pressure influencing progression and remission of diabetic retinopathy: a longitudinal cohort study in GoDARTS. Diabetes Care. 2013;36:3979–84 (PMID: 24170761).
Cushman WC, Evans GW, Byington RP, Goff DC Jr., Grimm RH Jr., et al., ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85 (PMID: 20228401).
Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481 (PMID: 31375757).
Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–9 (PMID: 10675071).
Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al., LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004–10 (PMID: 11937179).
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9 (PMID: 11565518).
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–28 (PMID: 19052124).
Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, et al., COLM Investigators. Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. J Hypertens. 2014;32:2054–63 (PMID: 24999799).
Takihata M, Nakamura A, Kondo Y, Kawasaki S, Kimura M, Terauchi Y. Comparison of azelnidipine and trichlormethiazide in Japanese type 2 diabetic patients with hypertension: The COAT randomized controlled trial. PLoS ONE. 2015;10:E0125519 (PMID: 25938807).
Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al., ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59 (PMID: 18378520).
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al, ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–13 (PMID: 23121378).
Costa J, Borges M, David C, Vaz CA. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006;332:1115–24 (PMID: 16585050).
Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823–8 (PMID: 9549452).
Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, et al, Japan Diabetes Complications Study Group. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: Subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab. 2011;96:3448–56 (PMID: 21865372).
Hayashi T, Kawashima S, Itoh H, Yamada N, Sone H, Watanabe H, et al., Japan CDM Group. Low HDL cholesterol is associated with the risk of stroke in elderly diabetic individuals: Changes in the risk for atherosclerotic diseases at various ages. Diabetes Care. 2009;32:1221–23 (PMID: 19509009).
Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation. 2014;129:999–1008 (PMID: 24352521).
Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ. The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2012;11:109 (PMID: 22978715).
Heilbronn LK, Noakes M, Clifton PM. Effect of energy restriction, weight loss, and diet composition on plasma lipids and glucose in patients with type 2 diabetes. Diabetes Care. 1999;22:889–95 (PMID: 10372237).
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al., CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96 (PMID: 15325833).
Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet. 2008;371:117–25 (PMID: 18191683).
Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16 (PMID: 12814710).
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al, FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61 (PMID: 16310551).
Allemann S, Diem P, Egger M, Christ ER, Stettler C. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. Curr Med Res Opin. 2006;22:617–23 (PMID: 16574044).
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al, SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92 (PMID: 21663949).
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al, IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397 (PMID: 26039521).
Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: A prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941–50 (PMID: 28927706).
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86 (PMID: 11786451).
Yasue H, Ogawa H, Tanaka H, Miyazaki S, Hattori R, Saito M, et al., Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Am J Cardiol. 1999;83:1308–13 (PMID: 10235086).
De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009;339:B4531 (PMID: 19897665).
Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al., Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–41 (PMID: 18997198).
Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, et al., Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial Investigators. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care. 2011;34:280–5 (PMID: 21270185).
Okada S, Morimoto T, Ogawa H, Kanauchi M, Nakayama M, Uemura S, et al, Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial Investigators. Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: A subanalysis of the JPAD trial. Diabetes Care. 2011;34:1277–83 (PMID: 21515838).
Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90:625–8 (PMID: 12231089).
Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90:1314–9 (PMID: 12480040).
Shinohara Y, Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients: subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis. 2008;26:63–70 (PMID: 18511873).
Sardar P, Udell JA, Chatterjee S, Bansilal S, Mukherjee D, Farkouh ME. Effect of intensive versus standard blood glucose control in patients with type 2 diabetes mellitus in different regions of the world: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2015;4:E001577 (PMID: 25944874).
Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343:D6898 (PMID: 22115901).
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:D4169 (PMID: 21791495).
Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288–98 (PMID: 19655124).
Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al, VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197–206 (PMID: 26039600).
Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, et al, ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371:1392–406 (PMID: 25234206).
Gerstein HC, Miller ME, Ismail-Beigi F, Largay J, McDonald C, Lochnan HA, et al, ACCORD Study Group. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet. 2014;384:1936–41 (PMID: 25088437).
Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: A meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60:1620–9 (PMID: 28770324).
Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D’Agostino RB Sr, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296:2572–81 (PMID: 17101640).
Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al., PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561–73 (PMID: 18378631).
van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. α-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005;28:154–63 (PMID: 15616251).
Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6 (PMID: 14683737).
Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, et al, EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis. Lancet Diabetes Endocrinol. 2018;6:105–13 (PMID: 29221659).
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139:2022–31 (PMID: 30786725).
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–701 (PMID: 30291106).
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41:255–323 (PMID: 31497854).
Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Shizuta S, Ehara N, et al. Long-term outcomes of coronary-artery bypass graft surgery versus percutaneous coronary intervention for multivessel coronary artery disease in the bare-metal stent era. Circulation. 2008;118(Suppl):S199–209 (PMID: 18824755).
Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28:2901–7 (PMID: 16306552).
Kasai T, Miyauchi K, Kajimoto K, Kubota N, Kurata T, Daida H. Influence of diabetes on >10-year outcomes after percutaneous coronary intervention. Heart Vessels. 2008;23:149–54 (PMID: 18484156).
Motomura N, Miyata H, Tsukihara H, Okada M, Takamoto S. Japan Cardiovascular Surgery Database Organization: first report on 30-day and operative mortality in risk model of isolated coronary artery bypass grafting in Japan. Ann Thorac Surg. 2008;86:1866–72 (PMID: 19021998).
Investigators BARI. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007;49:1600–6 (PMID: 17433949).
Investigators BARI. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol. 2000;35:1122–9 (PMID: 10758950).
Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al., FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367:2375–84 (PMID: 23121323).
Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, et al., FREEDOM Follow-On Study Investigators. Long-term survival following multivessel revascularization in patients with diabetes: The FREEDOM follow-on study. J Am Coll Cardiol. 2019;73:629–38 (PMID: 30428398).
Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al, SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961–72 (PMID: 19228612).
Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Berti S, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: Comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol. 2010;55:1067–75 (PMID: 20079596).
Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS guidelines on myocardial revascularization: The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2019;40:87–165 (PMID: 30165437).
Nasu K, Tsuchikane E, Katoh O, Fujita H, Surmely JF, Ehara M, et al. Plaque characterisation by Virtual Histology intravascular ultrasound analysis in patients with type 2 diabetes. Heart. 2008;94:429–33 (PMID: 17646194).
Amano T, Matsubara T, Uetani T, Nanki M, Marui N, Kato M, et al. Abnormal glucose regulation is associated with lipid-rich coronary plaque: relationship to insulin resistance. JACC Cardiovasc Imaging. 2008;1:39–45 (PMID: 19356403).
Uetani T, Amano T, Harada K, Kitagawa K, Kunimura A, Shimbo Y, et al. Impact of insulin resistance on post-procedural myocardial injury and clinical outcomes in patients who underwent elective coronary interventions with drug-eluting stents. JACC Cardiovasc Interv. 2012;5:1159–67 (PMID: 23174640).
Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355:773–8 (PMID: 10711923).
Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, et al. Effect of acute hyperglycemia on the ischemic preconditioning effect of prodromal angina pectoris in patients with a first anterior wall acute myocardial infarction. Am J Cardiol. 2003;92:288–91 (PMID: 12888134).
Ishii H, Ichimiya S, Kanashiro M, Amano T, Matsubara T, Murohara T. Effects of intravenous nicorandil before reperfusion for acute myocardial infarction in patients with stress hyperglycemia. Diabetes Care. 2006;29:202–6 (PMID: 16443860).
Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, et al., REACH Registry Investigators. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: Outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Circulation. 2015;132:923–31 (PMID: 26152709).
Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305–13 (PMID: 12151467).
Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27:1879–84 (PMID: 15277411).
Aune D, Sen A, Norat T, Janszky I, Romundstad P, Tonstad S, et al. Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. Circulation. 2016;133:639–49 (PMID: 26746176).
Pandey A, LaMonte M, Klein L, Ayers C, Psaty BM, Eaton CB, et al. Relationship between physical activity, body mass index, and risk of heart failure. J Am Coll Cardiol. 2017;69:1129–42 (PMID: 28254175).
Savji N, Meijers WC, Bartz TM, Bhambhani V, Cushman M, Nayor M, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Fail. 2018;6:701–9 (PMID: 30007554).
Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, et al. Dose–response relationship between physical activity and risk of heart failure: a meta-analysis. Circulation. 2015;132:1786–94 (PMID: 26438781).
Echouffo-Tcheugui JB, Butler J, Yancy CW, Fonarow GC. Association of physical activity or fitness with incident heart failure: a systematic review and meta-analysis. Circ Heart Fail. 2015;8:853–61 (PMID: 26175539).
Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, et al., Look AHEAD Research Group. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: A post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4:913–21 (PMID: 27595918).
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91 (PMID: 18256393).
Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving HH, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59:2298–307 (PMID: 27531506).
Oellgaard J, Gæde P, Rossing P, Rørth R, Køber L, Parving HH, et al. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia. 2018;61:1724–33 (PMID: 29850922).
Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772–6 (PMID: 13678870).
McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767–71 (PMID: 13678869).
Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529–38 (PMID: 12742294).
Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, et al., MERIT-HF Study Group. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J. 2005;149:159–67 (PMID: 15660048).
Haas SJ, Vos T, Gilbert RE, Krum H. Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J. 2003;146:848–53 (PMID: 14597934).
Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al., GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–36 (PMID: 15536109).
Arnold SV, Spertus JA, Lipska KJ, Lanfear DE, Tang F, Grodzinsky A, et al. Type of β-blocker use among patients with versus without diabetes after myocardial infarction. Am Heart J. 2014;168(273–279):e1 (PMID: 25173537).
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al., EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21 (PMID: 21073363).
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al., Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17 (PMID: 10471456).
Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol. 2009;54:422–8 (PMID: 19628117).
Elder DH, Singh JS, Levin D, Donnelly LA, Choy AM, George J, et al. Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study. Eur J Heart Fail. 2016;18:94–102 (PMID: 26663216).
Connelly KA, Yan AT, Leiter LA, Bhatt DL, Verma S. Cardiovascular implications of hypoglycemia in diabetes mellitus. Circulation. 2015;132:2345–50 (PMID: 26667098).
Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T, et al., American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Hypertension; and Council on Quality and Outcomes Research. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a Scientific Statement from the American Heart Association. Circulation. 2016;134:E535–78 (PMID: 27799274).
DeFronzo RA, Chilton R, Norton L, Clarke G, Ryder RE, Abdul-Ghani M. Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor. Diabetes Obes Metab. 2016;18:454–62 (PMID: 26919068).
Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345–51 (PMID: 16186261).
Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jørgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010;53:2546–53 (PMID: 20838985).
Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011;4:53–8 (PMID: 20952583).
Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6:395–402 (PMID: 23508758).
Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB, Stanifer JW, Mock CK, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med. 2017;166:191–200 (PMID: 28055049).
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al., SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–26 (PMID: 23992601).
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al., EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35 (PMID: 23992602).
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al., TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–42 (PMID: 26052984).
Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al., CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69–79 (PMID: 30418475).
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al., REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–30 (PMID: 31189511).
Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, et al., Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519–29 (PMID: 30291013).
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al., EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–39 (PMID: 28910237).
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al., PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–51 (PMID: 31185157).
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al., SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44 (PMID: 27633186).
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al., LEADER Steering Committee. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22 (PMID: 27295427).
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al., ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57 (PMID: 26630143).
Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al, NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316:500–8 (PMID: 27483064).
Sharma A, Cooper LB, Fiuzat M, Mentz RJ, Ferreira JP, Butler J, et al. Antihyperglycemic therapies to treat patients with heart failure and diabetes mellitus. JACC Heart Fail. 2018;6:813–22 (pmid: 30098964).
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–9 (PMID: 30424892).
Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, et al. EMPEROR Trials Program: The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail. 2017;19:1390–400 (PMID: 28836359).
McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, et al., DAPA-HF Committees and Investigators. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 20s19;21:665–75 (PMID: 30895697).
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al., DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–8 (PMID: 31535829).
Tadic M, Cuspidi C. Type 2 diabetes mellitus and atrial fibrillation: From mechanisms to clinical practice. Arch Cardiovasc Dis. 2015;108:269–76 (PMID: 25858534).
Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al., Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33 (PMID: 12466506).
Inoue H, Atarashi H, Kamakura S, Koretsune Y, Kumagai K, Mitamura H, et al, JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J 2014;78:1997–2021 (PMID: 24965079).
Katoh T, Iinuma H, Inoue H, Ohe T, Ogawa S, Kasanuki H, et al. Multicenter prospective nonrandomized study of long-term antiarrhythmic drug therapy in patients with tachyarrhythmias: Japanese Antiarrhythmics Long-Term Study-2 (JALT-2 Study). Jpn Circ J. 2001;65:275–8 (PMID: 11316122).
Ogawa S, Yamashita T, Yamazaki T, Aizawa Y, Atarashi H, Inoue H, et al., J-RHYTHM Investigators. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J. 2009;73:242–48 (PMID: 19060419).
Della Rocca DG, Mohanty S, Trivedi C, Di Biase L, Natale A. Percutaneous treatment of non-paroxysmal atrial fibrillation: a paradigm shift from pulmonary vein to non-pulmonary vein trigger ablation? Arrhythm Electrophysiol Rev. 2018;7:256–60 (PMID: 30588313).
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100 (PMID: 20299623).
Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173–80 (PMID: 21111555).
Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, et al., Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37:447–51 (PMID: 16385088).
Hart RG, Sherman DG, Easton JD, Cairns JA. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology. 1998;51:674–81 (PMID: 9748009).
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al., RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51 (PMID: 19717844).
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al., ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104 (PMID: 24251359).
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al., ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91 (PMID: 21830957).
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al., ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365: 981–92 (PMID: 21870978).
Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al., J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: The J-ROCKET AF study. Circ J. 2012;76:2104–111 (PMID: 22664783).
Evans IL, Sayers MS, Gibbons AJ, Price G, Snooks H, Sugar AW. Can warfarin be continued during dental extraction? Results of a randomized controlled trial. Br J Oral Maxillofac Surg. 2002;40:248–52 (PMID: 12054719).
Japanese Society of Dentistry for Medically Compromised Patients, Japanese Society of Oral Maxillofacial Surgery, and Japanese Society of Gerodontology. Scientific evidence-based guidelines for dental extraction in patients with antithrombotic therapy. Tokyo: Gakujutsusha; 2010 (in Japanese).
Fujimoto K, Fujishiro M, Kato M, Higuchi K, Iwakiri R, Sakamoto C, et al. Japan Gastroenterological Endoscopy Society: guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc. 2014;26:1–14 (PMID: 24215155).
Kato M, Uedo N, Hokimoto S, Ieko M, Higuchi K, Murakami K, et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment: 2017 appendix on anticoagulants including direct oral anticoagulants. Dig Endosc. 2018;30:433–40 (PMID: 29733468).
van Veldhuisen DJ, Van Gelder IC, Ahmed A, Gheorghiade M. Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not? Eur Heart J. 2013;34:1468–70 (PMID: 23324547).
Mujović N, Marinković M, Lenarczyk R, Tilz R, Potpara TS. Catheter ablation of atrial fibrillation: An overview for clinicians. Adv Ther. 2017;34:1897–917 (PMID: 28733782).
Acknowledgements
We appreciate the special assistance given by Mr. Takashi Itakiyo and Ms. Koko Okuda, as well as the office staff of the Japanese Circulation Society and the Japan Diabetes Society in support of this work.
Collaborators’ list of our manuscript titled “Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People with Type 2 Diabetes and Pre-Diabetes: A Consensus Statement Jointed from The Japanese Circulation Society and The Japan Diabetes Society”
Tetsuya Amano, Toshihisa Anzai, Tetsuya Babazono, Masanori Emoto, Keiichi Fukuda, Nobuhisa Hagiwara, Ken-ichi Hirata, Yuji Ikari, Takanori Ikeda, Chisato Izumi, Masahiro Jinzaki, Hideaki Kaneto, Hideki Katagiri, Takeshi Kimura, Yoshio Kobayashi, Koji Maemura, Satoaki Matoba, Tetsuo Minamino, Yoshihide Mitani, Shin-ichiro Miura, Yoshihio Morino, Jiro Nakamura, Yoshihiko Nishio, Wataru Ogawa, Mitsuru Ohishi, Hiroyuki Okura, Minoru Ono, Yasushi Sakata, Asako Sato, Akira Shimada, Wataru Shimizu, Iichiro Shimomura, Ichiro Shiojima, Masayuki Takamura, Yasutomo Takeishi, Kazuo Tanemoto, Yukio Tanizawa, Yasuo Terauchi, Kazuyuki Tobe, Yayoi Tetsuou Tsukada, Hirotaka Watada, Toshimasa Yamauchi, Masafumi Yano, Narihito Yoshioka.
Funding
None.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
H. Ito., T.M., I.K., K.N. are members of the Circulation Journal’s editorial team. Disclosure of individual potential conflicts of interest. (1) Compensation (officers and advisors) 1 million yen or more. (2) Stock profit 1 million yen or more or holding 5% or more. (3) Patent fee 1 million yen or more. (4) Lecturer’s fee 500,000 yen or more. (5) Manuscript fee 500,000 yen or more. (6) Research expenses and grants 1 million yen or more. (7) Scholarship (encouragement) donation 1 million yen or more. (8) Endowed course 1 million yen or more. (9) Travel expenses, gifts 50,000 yen or more. B. Spouse of Declarer.
Eiichi Araki: (4), AstraZeneca K.K., MSD K.K., ONO PHARMACEUTICAL CO., LTD., Kowa Company, Ltd., Sanofi K.K., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, NOVO NORDISK PHARMA LTD. (7), Astellas Pharma Inc., MSD K.K., ONO PHARMACEUTICAL CO., LTD., Sanofi K.K, DAIICHI SANKYO CO., LTD, TAISHO PHARMACEUTICAL CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., TAKEDA PHARMACEUTICAL COMPANY LIMITED, Mitsubishi Tanabe Pharma Corporation, NIPPON BOEHRINGER INGELHEIM CO., LTD., NOVARTIS PHARMA K.K., NOVO NORDISK PHARMA LTD., BAYER YAKUHIN, LTD., PFIZER JAPAN INC. (8), MSD K.K., ONO PHARMACEUTICAL CO., LTD., Terumo Corporation.
Hideki Ishii: (4), Astellas Pharma Inc., AstraZeneca K.K., MSD K.K., DAIICHI SANKYO CO., LTD, CHUGAI PHARMACEUTICAL CO., LTD., BAYER YAKUHIN, LTD., PFIZER JAPAN INC., Bristol-Myers Squibb K.K.
Hiroshi Ito: (4), Astellas Pharma Inc., AstraZeneca K.K., MSD K.K., DAIICHI SANKYO CO., LTD, CHUGAI PHARMACEUTICAL CO., LTD., BAYER YAKUHIN, LTD., PFIZER JAPAN INC., Bristol-Myers Squibb K.K. (6), Kowa Company, Ltd., NOVARTIS PHARMA K.K. (7), Astellas Pharma Inc., MSD K.K., ONO PHARMACEUTICAL CO., LTD., Kowa Company, Ltd., Sanofi K.K., DAIICHI SANKYO CO., LTD, TAISHO PHARMACEUTICAL CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., TAKEDA PHARMACEUTICAL COMPANY LIMITED, Mitsubishi Tanabe Pharma Corporation, NIPPON BOEHRINGER INGELHEIM CO., LTD., MOCHIDA PHARMACEUTICAL CO., LTD. (8), Medtronic Japan Co., Ltd.
Nobuya Inagaki: (4), Astellas Pharma Inc., MSD K.K., ONO PHARMACEUTICAL CO., LTD., Kowa Company, Ltd., TAKEDA PHARMACEUTICAL COMPANY LIMITED, Mitsubishi Tanabe Pharma Corporation, NIPPON BOEHRINGER INGELHEIM CO., LTD., NOVO NORDISK PHARMA LTD. (6), DAIICHI SANKYO CO., LTD, Terumo Corporation, Drawbridge Inc. (7), Astellas Pharma Inc., MSD K.K., ONO PHARMACEUTICAL CO., LTD., KISSEI PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd., Sanofi K.K, SANWA KAGAKU KENKYUSHO CO., LTD., DAIICHI SANKYO CO., LTD, Sumitomo Dainippon Pharma Co., Ltd., TAKEDA PHARMACEUTICAL COMPANY LIMITED, Mitsubishi Tanabe Pharma Corporation, TEIJIN PHARMA Limited, ELI LILLY JAPAN K.K., Japan Tobacco Inc., NIPPON BOEHRINGER INGELHEIM CO., LTD., NOVARTIS PHARMA K.K., NOVO NORDISK PHARMA LTD., Life Scan Japan.
Kenjiro Imai: None to disclose.
Kohjiro Ueki: (4), Astellas Pharma Inc., AstraZeneca K.K., MSD K.K., ONO PHARMACEUTICAL CO., LTD., Sanofi K.K, DAIICHI SANKYO CO., LTD, Sumitomo Dainippon Pharma Co., Ltd., TAKEDA PHARMACEUTICAL COMPANY LIMITED, Mitsubishi Tanabe Pharma Corporation, NIPPON BOEHRINGER INGELHEIM CO., LTD., NOVO NORDISK PHARMA LTD. (6), Astellas Pharma Inc., Abbott Japan LLC., MSD K.K., ELI LILLY JAPAN K.K., NIPPON BOEHRINGER INGELHEIM CO., LTD., NOVO NORDISK PHARMA LTD. (7), Astellas Pharma Inc., MSD K.K., ONO PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., TAKEDA PHARMACEUTICAL COMPANY LIMITED, Mitsubishi Tanabe Pharma Corporation, NIPPON BOEHRINGER INGELHEIM CO., LTD., NOVO NORDISK PHARMA LTD.
Takashi Kadowaki: (4), MSD Corporation, Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Kowa Pharmaceutical Co., Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co., Ltd., AstraZeneca K.K., Sumitomo Dainippon Pharma Co., Ltd., Sanofi K.K., Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Taisho Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd. (6), MSD Corporation, Daiichi Sankyo Co., Ltd., Novo Nordisk Pharma Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd. (8), Asahi Mutual Life Insurance Company, Takeda Pharmaceutical Co., Ltd., TERUMO Corporation, MSD Corporation, Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co., Ltd.
Issei Komuro: (4), Astellas Pharma Inc., MSD K.K., Amgen Astellas BioPharma K.K., AstraZeneca K.K., Pfizer Japan Inc., ONO PHARMACEUTICAL CO. LTD., DAIICHI SANKYO COMPANY, LIMITED., Takeda Pharmaceutical Company Limited., Mitsubishi Tanabe Pharma Corporation, BAYER YAKUHIN, LTD, Bristol-Myers Squibb Company, Nippon Boehringer Ingelheim Co. Ltd., Actelion Pharmaceuticals Japan Ltd. (6), QVIA Services Japan, ONO PHARMACEUTICAL CO. LTD. (7), Dainippon Sumitomo Pharma Co. Ltd., Terumo Corporation, DAIICHI SANKYO COMPANY, LIMITED, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, TEIJIN PHARMA LIMITED.
Masataka Sata: (4), Amgen Astellas BioPharma K.K., Astellas Pharma Inc., MSD K.K., KOWA PHARMACEUTICAL COMPANY LTD., DAIICHI SANKYO CO., LTD, TAKEDA PHARMACEUTICAL COMPANY LIMITED, Mitsubishi Tanabe Pharma Corporation, NIPPON BOEHRINGER INGELHEIM CO., LTD., BAYER YAKUHIN, LTD., Bristol-Myers Squibb K.K. (6), DAIICHI SANKYO CO., LTD, NIPPON BOEHRINGER INGELHEIM CO., LTD., BAYER YAKUHIN, LTD. (7), Astellas Pharma Inc., MSD K.K., DAIICHI SANKYO CO., LTD, TAKEDA PHARMACEUTICAL COMPANY LIMITED, Mitsubishi Tanabe Pharma Corporation. (8), NIPPON BOEHRINGER INGELHEIM CO., LTD.
Takehiro Sugiyama: (8), JMDC.
Atsushi Tanaka: (6), GlaxoSmithKline K.K.
Koichi Node: (4), Astellas Pharma Inc., AstraZeneca K.K., MSD K.K., OTSUKA PHARMACEUTICAL Co., Ltd., ONO PHARMACEUTICAL CO., LTD., KOWA PHARMACEUTICAL COMPANY LTD., DAIICHI SANKYO CO., LTD, TAKEDA PHARMACEUTICAL COMPANY LIMITED, Mitsubishi Tanabe Pharma Corporation, ELI LILLY JAPAN K.K., NIPPON BOEHRINGER INGELHEIM CO., LTD., BAYER YAKUHIN, LTD. (6), Asahi Kasei Corp., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, TEIJIN PHARMA Limited, Terumo Corporation, NIPPON BOEHRINGER INGELHEIM CO., LTD., BAYER YAKUHIN, LTD., Eli Lilly and Company (USA). (7), Astellas Pharma Inc., ONO PHARMACEUTICAL CO., LTD., DAIICHI SANKYO CO., LTD, TAKEDA PHARMACEUTICAL COMPANY LIMITED, TEIJIN PHARMA Limited, ELI LILLY JAPAN K.K., NIPPON BOEHRINGER INGELHEIM CO., LTD., NOVARTIS PHARMA K.K., BAYER YAKUHIN, LTD., PFIZER JAPAN INC., Bristol-Myers Squibb K.K., Sanofi K.K.
Toyoaki Murohara: (4), Actelion Pharmaceuticals Japan Ltd., Amgen Astellas BioPharma K.K., AstraZeneca K.K., MSD K.K., Kowa Company, Ltd., DAIICHI SANKYO CO., LTD, TAKEDA PHARMACEUTICAL COMPANY LIMITED, Mitsubishi Tanabe Pharma Corporation, NIPPON BOEHRINGER INGELHEIM CO., LTD., BAYER YAKUHIN, LTD. (7), Astellas Pharma Inc., OTSUKA PHARMACEUTICAL Co., Ltd., DAIICHI SANKYO CO., LTD, TAKEDA PHARMACEUTICAL COMPANY LIMITED, TEIJIN PHARMA Limited, BAYER YAKUHIN, LTD.
Shunsuke Yamane: (7), Mitsubishi Tanabe Pharma Corporation.
Disclosure of Potential Conflicts of Interest as Organization. Companies that funded the activities of the Japanese Circulation Society from January 1, 2017 to December 31, 2019.
Co-sponsored seminar: Actelion Pharmaceuticals Japan Ltd., Asahi Kasei ZOLL Medical Corporation., Amgen Astellas BioPharma K.K., Astellas Pharma Inc., AstraZeneca K.K., Abbott Japan LLC., Abbott Vascular Japan Co., Ltd., Abbott Medical Japan LLC, Alere Medical Co.,Ltd., Alnylam Japan, AnGes, Inc., EA Pharma Co.,Ltd., A&D Company, Limited., Eisai Co., Ltd., AEGERION PHARMACEUTICALS K.K., Edwards Lifesciences Corporation., MSD K.K., LSI Medience Corporation, OTSUKA PHARMACEUTICAL Co., Ltd., ONO PHARMACEUTICAL CO., LTD., Japanese Coronary Spasm Association, CANON MEDICAL SYSTEMS CORPORATION, Kyowa Medex Co., Ltd, Cuorips Inc., GlaxoSmithKline K.K., KOWA PHARMACEUTICAL COMPANY LTD., Kotobuki pharmaceutical Co., Ltd., Sanofi K.K, Sawai Pharmaceutical Co., Ltd., Sun Medical Technology Research Corp., SANWA KAGAKU KENKYUSHO CO., LTD., CSL Behring K.K., Siemens Healthcare Diagnostics K.K., JCR Pharmaceuticals Co., Ltd., SHIONOGI & CO., LTD., CMIC HOLDINGS Co., Ltd., SUZUKEN CO.,LTD., SEKISUI MEDICAL CO., LTD., Century Medical, Inc., St. Jude Medical Japan Co., Ltd., DAIICHI SANKYO CO., LTD, TAISHO PHARMACEUTICAL CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., TAKEDA PHARMACEUTICAL COMPANY LIMITED, Mitsubishi Tanabe Pharma Corporation, CHUGAI PHARMACEUTICAL CO., LTD., TSUMURA & CO., DS Pharma Biomedical Co.,Ltd., Teijin Home Healthcare Limited, TEIJIN PHARMA Limited, Terumo Corporation, DENSO CORPORATION, TOSHIBA MEDICAL SYSTEMS CORPORATION, Tosoh Corporation., Toray Industries, Inc., TOA EIYO LTD., Nipro Corporation, Abiomed Japan K.K., ELI LILLY JAPAN K.K., Japanese Organization for Medical Device Development, Inc., The Japanese Society of Nuclear Medicine, Nippon Kayaku Co.,Ltd., W. L. Gore & Associates G.K., The Japanese Society of Nuclear Cardiology., Nippon Shinyaku Co., Ltd., NIPPON BOEHRINGER INGELHEIM CO., LTD., Nihon Medi-Physics Co.,Ltd., Medtronic Japan Co., Ltd., Japan Lifeline Co.,Ltd., NOVO NORDISK PHARMA LTD., BAYER YAKUHIN, LTD., BIOTRONIK Japan, Inc., PFIZER JAPAN INC., Philips Respironics GK, FUKUDA LIFE TECH K.K., FUKUDA DENSHI CO., LTD., FUJIFILM RI Pharma Co.,Ltd., FUJIFILM Medical Co., Ltd, FUJIFILM Toyama Chemical Co., Ltd., FUJIYAKUHIN Co., Ltd., FUJIREBIO Inc., Bristol-Myers Squibb K.K, Boston Scientific Japan KK, Volcano Japan Co., Ltd., MYLAN EPD G.K., MOCHIDA PHARMACEUTICAL CO., LTD., ResMed.KK.
Supporting member: Astellas Pharma Inc., AstraZeneca K.K., IGAKU-SHOIN Ltd., Ueda Japan Radio Co., Ltd., Eisai Co., Ltd., MSD K.K., Element-HRC, OTSUKA PHARMACEUTICAL Co., Ltd., Omura Printing Co., Ltd., OMRON HEALTHCARE Co., Ltd., Kaito, Gakuju Shoin, KK, KAKEN PHARMACEUTICAL CO., LTD., Kyoto Pharmaceutical Industries, Ltd., KYOWA KIKAKU Ltd, Goodman Co.,LTD, Kawakita Printing Co., Ltd., KOWA PHARMACEUTICAL COMPANY LTD., Congrès Inc, Sanofi K.K, GE Healthcare Japan Corp., Siemens Healthcare K.K., JTB corp. Western Japan MICE division, SHIMADZU CORPORATION Medical project planning department, St. Jude Medical Japan Co., Ltd., Sompo Japan Insurance Inc., DAIICHI SANKYO CO., LTD Marketing Department, TAISHO PHARMACEUTICAL CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, TEIJIN PHARMA Limited, Tokyo Planning Center KK., Toray Medical Co.,Ltd., TOA EIYO LTD., TORII PHARMACEUTICAL CO., LTD., Nankodo Co., Ltd., Nissen Techno Comms, Nipro Corporation, Japan Convention Services, Inc., Zeon Corporation, NIPPON BOEHRINGER INGELHEIM CO., LTD., Nihon Medi-Physics Co.,Ltd., Medtronic Japan Co., Ltd., BAYER YAKUHIN, LTD., BIOTRONIK Japan, Inc., Hitachi Aloka Medical, Ltd, PFIZER JAPAN INC., FUKUDA COLIN Co.,Ltd., Fukuda AD Agency, FUKUDA DENSHI CO., LTD., Bristol-Myers Squibb K.K., Proactive.Inc, HEIWA BUSSAN CO.,LTD, MEDICAL VIEW CO.,LTD., Medical Review Co., Ltd., MOCHIDA PHARMACEUTICAL CO., LTD., YOSHIDA PRINTING GROUP., Radiometer K.K., Roche Diagnostics K.K.
Research grant; none; Honoring program; Japan Heart Foundation.
Companies that funded the activities of the Japan Diabetes Society from January 1, 2017 to December 31, 2019.
Co-sponsored seminar: ARKRAY, Inc., ARKRAY Marketing, Inc., Asahi Kasei Pharma Corporation., Ajinomoto Co., Inc., ASKA Pharmaceutical Co.,Ltd., Astellas Pharma Inc., AstraZeneca K.K., Abbott Japan LLC., Abbott Vascular Japan Co., Ltd., Alere Medical Co.,Ltd., InBody Japan Inc., Welbe, Inc., ARBROWN CO.,LTD., EIKEN CHEMICAL CO.,LTD., Eisai Co., Ltd., AEGERION PHARMACEUTICALS K.K., SRL, Inc., MSD K.K., LSI Medience Corporation, OTSUKA PHARMACEUTICAL Co., Ltd., ONO PHARMACEUTICAL CO., LTD., KAKEN PHARMACEUTICAL CO., LTD., KISSEI PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd., Kyowa Medex Co., Ltd, Gilead Sciences, Inc., Kracie Pharmaceutical, Ltd., Covidien Japan Inc., Kowa Company, Ltd., Cosmic Corporation Co., Ltd., Kotobuki pharmaceutical Co., Ltd., Sanofi K.K, SANWA KAGAKU KENKYUSHO CO., LTD., Santen Pharmaceutical Co., Ltd., Johnson & Johnson K.K., DAIICHI SANKYO CO., LTD, TAISHO PHARMACEUTICAL CO., LTD., TAISHO PHARMACEUTICAL CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, TAKEDA PHARMACEUTICAL COMPANY LIMITED, Terumo Corporation, Nikkiso Co., Ltd., Nipro Corporation, ELI LILLY JAPAN K.K., NIPPON BOEHRINGER INGELHEIM CO., LTD., Nippon Becton Dickinson Company, Ltd., Medtronic Japan Co., Ltd., NOVARTIS PHARMA K.K., NOVO NORDISK PHARMA LTD., BAYER YAKUHIN, LTD., Hakubaku Co.,Ltd., PFIZER JAPAN INC., FUKUDA COLIN Co.,Ltd., FUKUDA DENSHI CO., LTD., FUJIFILM Pharma Co., Ltd., FUJIFILM Toyama Chemical Co., Ltd., Healthy Network, HORIBA, Ltd., MYLAN EPD G.K., MOCHIDA PHARMACEUTICAL CO., LTD., UNEX corporation, LifeScan Japan, RIZAP GROUP, Inc., Roche DC Japan K.K.
Supporting member: ARKRAY Marketing, Inc., Astellas Pharma Inc., AstraZeneca K.K., Abbott Japan LLC., EA Pharma Co.,Ltd., Eisai Co., Ltd., H + B Life Science Co.,Ltd., SRL, Inc., MSD K.K., ONO PHARMACEUTICAL CO., LTD., KAKEN PHARMACEUTICAL CO., LTD., KISSEI PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd., Kowa Company, Ltd., Sanofi K.K, SANWA KAGAKU KENKYUSHO CO., LTD., SHIONOGI & CO., LTD., SYSMEX CORPORATION, Johnson & Johnson K.K., SEKISUI MEDICAL CO., LTD., DAIICHI SANKYO CO., LTD, TAISHO PHARMACEUTICAL CO., LTD., TAISHO PHARMACEUTICAL CO., LTD., Sumitomo Dainippon Pharma Co., Ltd., TAKEDA PHARMACEUTICAL COMPANY LIMITED, Mitsubishi Tanabe Pharma Corporation, CHUGAI PHARMACEUTICAL CO., LTD., Terumo Corporation, Tosoh Corporation., Nipro Corporation, ELI LILLY JAPAN K.K., Japan Tobacco Inc., NIPPON BOEHRINGER INGELHEIM CO., LTD., Medtronic Japan Co., Ltd., NOVO NORDISK PHARMA LTD., Panasonic Healthcare Co., Ltd., PHC Holdings Corporation, Bunkodo Co., Ltd., HORIBA, Ltd., LifeScan Japan, Roche DC Japan K.K.
Research grant: Abbott Japan LLC., MSD K.K., Sanofi K.K, TAKEDA PHARMACEUTICAL COMPANY LIMITED, ELI LILLY JAPAN K.K., NIPPON BOEHRINGER INGELHEIM CO., LTD., NOVO NORDISK PHARMA LTD.
Honoring program: Sanofi K.K., ELI LILLY JAPAN K.K., NOVO NORDISK PHARMA LTD (The company name is as of December 2019).
Ethical statement
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This statement is based on the “Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Pre-Diabetes: A Consensus Statement Jointed from The Japanese Circulation Society and The Japan Diabetes Society” (ISBN978-4-524-22818-8), which was published in Japanese by Nankodo Co., Ltd. (©The Japanese Circulation Society, The Japan Diabetes Society, 2020) and is jointly published in the Circulation Journal (official English journal of the JCS: doi 10.1253/circj.CJ-20-0865) and Diabetology International (official English journal of the JDS).
About this article
Cite this article
Araki, E., Tanaka, A., Inagaki, N. et al. Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. Diabetol Int 12, 1–51 (2021). https://doi.org/10.1007/s13340-020-00471-5
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13340-020-00471-5